戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1 en reported to cyclize to pyroglutamic acid (pGlu) during liquid chromatography (LC)-mass spectrometr
2 he sensitivity and accuracy of Gln, Glu, and pGlu quantitation by electrospray ionization-based mass
3  that we developed to separate Gln, Glu, and pGlu, we found that free Gln and Glu cyclize to pGlu in
4 stable GLP-1 and CCK mimetics exendin-4 and (pGlu-Gln)-CCK-8, respectively.
5 -derived TRH-enhancing decapeptide, and EEP (pGlu-Glu-Pro-NH(2)).
6      Administration of the peptides, except (pGlu-Gln)-CCK-8 alone, in combination with glucose signi
7  but cyclization of free Gln and Glu to free pGlu during LC-MS analysis has not been well-characteriz
8 in-G, a 16-amino acid O-linked glycopeptide (pGlu-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro-Tyr
9 he novel (pGlu-Gln)-CCK-8/exendin-4 hybrid, (pGlu-Gln)-CCK-8 alone, or (pGlu-Gln)-CCK-8 in combinatio
10 lian gonadotropin-releasing hormone (GnRH I: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) stimulates
11  of these, designated type II GnRH (GnRH II: pGlu-His-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2), is conserved
12  actions and therapeutic utility of a novel (pGlu-Gln)-CCK-8/exendin-4 hybrid peptide compared with t
13     Twice-daily administration of the novel (pGlu-Gln)-CCK-8/exendin-4 hybrid, (pGlu-Gln)-CCK-8 alone
14 correlations are suited for the detection of pGlu in denatured proteins.
15 biguous identification and quantification of pGlu in intact mAbs with natural isotope distribution by
16 d an advantageous system in which removal of pGlu from the heavy chain was determined as a ratio of t
17 3)C and (15)N random coil chemical shifts of pGlu in short reference peptides led to the identificati
18 -Ser-Asn-Ala-Thr-Lys-Lys-Pro-Tyr-Ile-Leu-OH, pGlu is pyroglutamate) from Conus geographus venom.
19 RIA) revealed that pGlu-Tyr-Pro-NH(2) and/or pGlu-Phe-Pro-NH(2) occur in amygdala, anterior cingulate
20 xendin-4 hybrid, (pGlu-Gln)-CCK-8 alone, or (pGlu-Gln)-CCK-8 in combination with exendin-4 for 21 day
21 , pGlu-His-Pro-NH(2)) and TRH-like peptides (pGlu-X-Pro-NH(2), where "X" can be any amino acid residu
22 thyrotropin-releasing hormone-like peptides (pGlu-X-Pro-NH(2), where "X" can be any amino acid residu
23                               Pyroglutamate (pGlu), a cyclization product of N-terminal Gln or Glu re
24  procedure for the removal of pyroglutamate (pGlu) by pyroglutamate aminopeptidase (PGAP) and demonst
25 r cleavage and subsequent pyroglutamylation (pGlu) of the newly formed N terminus.
26 ward protocol, and could detect and quantify pGlu, in agreement with available mass spectrometric dat
27  internal standards to correct for in-source pGlu formation, and (iii) user-optimized fragmentor volt
28 the EEP radioimmunoassay (RIA) revealed that pGlu-Tyr-Pro-NH(2) and/or pGlu-Phe-Pro-NH(2) occur in am
29                    HbA1c was reduced in the (pGlu-Gln)-CCK-8/exendin-4 hybrid and combined parent pep
30                                         This pGlu-CSP epitope is not targeted by current anti-PfCSP m
31 ximum of almost 100% of Gln was converted to pGlu in the ionization source, with the extent of conver
32 dration occur not only during cyclization to pGlu, but also during other reactions leading to differe
33 u, we found that free Gln and Glu cyclize to pGlu in the electrospray ionization source, revealing a
34 eleasing hormone (TRH) analogue [Leu(2)]TRH (pGlu-Leu-Pro-NH(2)), was covalently and bioreversibly mo
35 ected and immunoreactivity measured for TRH (pGlu-His-Pro-NH(2)); TRH-Gly, a TRH precursor; Ps4, a pr
36 ted that thyrotropin-releasing hormone (TRH, pGlu-His-Pro-NH(2)) and TRH-like peptides (pGlu-X-Pro-NH